Effects of medication in the elderly: From the pharmacological target to the risk/benefit assessment;Les effets des médicaments chez les sujets âgés: De la cible pharmacologique au bénéfice/risque

Therapie

Volumn , Issue 4, 2001, Pages 363-367

  Lassale, C ^a   Piette, F ^b   Jolliet, P ^c   Abadie, Eric ^d   Allain, Hervé ^e   Baumclou, Alain ^f   Bellissant, Eric ^e   Blin, Olivier ^f   Boutier, Christian ^f   Cellier, Dominic ^f   D'Allens, Hervé ^g   Damier, Philippe ^f   Eschwege, Eveline ^h   Farah, Soraya ^a   Guez, David ⁱ   Hugonot Diener, Laurence ^f   Jager, Martine ^d   Potel, Gilles ^j   Rosenzweig, Pierre ^k   Saint Salvi, Béatrice ^d   Spriet, Alain ^l   Vetel, Jean Marie ^f   more..

^a SANOFI   (France)

^b HÔPITAL CHARLES FOIX   (France)

^c UNIVERSITÉ DE NANTES   (France)

^d AFSSAPS   (France)

^e RENNES UNIVERSITY HOSPITAL   (France)

^f Pitié Salpétrière ^*  (France)

^g Glaxo Smith Kline

^h INSERM   (France)

ⁱ INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

^j HÔTEL DIEU   (France)

^k Sanofi Synthelabo Inc   (United Kingdom)

^l Spriet Conseil   (France)

more..

Author keywords

Drug response; Drug related iatrogenic effects; Elderly; International guidelines; Specific clinical studies

Indexed keywords

AGED; AGING; CLINICAL RESEARCH; CONFERENCE PAPER; DRUG CONTRAINDICATION; DRUG INDUCED DISEASE; DRUG METABOLISM; DRUG SAFETY; GERIATRIC PATIENT; HUMAN; IATROGENIC DISEASE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; ARTICLE; BIOTRANSFORMATION; CLINICAL TRIAL; DRUG UTILIZATION; FRANCE; HOSPITALIZATION; METABOLISM; METHODOLOGY; PATIENT SELECTION; PHARMACOKINETICS; PHYSIOLOGY; POSTMARKETING SURVEILLANCE; STATISTICS;

DRUG;

AGED; AGING; BIOTRANSFORMATION; CLINICAL TRIALS; DRUG UTILIZATION; FRANCE; HOSPITALIZATION; HUMANS; IATROGENIC DISEASE; PATIENT SELECTION; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; PRODUCT SURVEILLANCE, POSTMARKETING;

EID: 0034741196     PISSN: 00405957     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (24)

1. INED. Recensement de la population française, 1999.
2. Fourrier A, Dequae L, Chasleric A et al. Sociodemographic characteristic? and polypharmacy in elderly people: data from the PAQUID study. Post Mark Surv 1993; 7: 291-298.
3. Gonthier R. Cathebras P. Polypathologies du sujet âgé et réponses thérapeutiques: les pièges à éviter, Presse Med 1999; 28: 1780-1788.
4. Moore N, Imbs JL. Filets indésirables ehez la personne âgée: une analyse de la banque nationale de cas en pharmacovigilance. Rev Prat 1996; 46: 396-399.
5. Gonthier R, Cathebras P, Delhomme M. et al. Iatrogénèse médicamenteuse à l'origine d'une hospitalisation après 70 ans. Rev Med Interne 1994; 15 (suppl. 3): 343.
6. Manchon ND, Bercoff E, Lemarchand P et al. Fréquence et gravité des interactions médicamenteuses dans une population âgée: étude prospective concernant 639 malades. Rev Med Interne 1989; 10: 521-525.
7. Schmucker LD, Vesse SE, Are the elderly underrepresented in clinical drug trials? J Clin Pharmacol 1999; 39: 1103-1108.
8. Brennan TA, Leaple LL, Laird MN el al. Incidence of adverse events and negligence in hospitalized patients. Results of the Harvard Medical Practice Study I. N Engl J Med 1991; 324: 370-376.
9. ICH. Note for guidance on studies in support of special populations: Geriatrics, 1994.
10. FDA. Guideline for the study of drugs likely to be used in the elderly. November 1989.
11. Cameron JH, William OB. Clinical trials in the elderly. Should we do more? Drug Aging 1996: 9: 307-310.
12. Schwartz JB, Temple JR, Lemke HJ et al. Drug testing in the elderly. Pharmacol Ther 1992: 1715-1748.
13. Hutchins LF, Unger MJ, Crowley JJ et al. Underrepresentation of patients 65 years of age or older in cancer treatment trials. AWJ 1999; 341: 2061-2067.
14. Bayer A, Tadd W. Unjustified exclusion of elderly people from studies submitted to research ethics commitee for aproval: descriptive study. AWJ 2000; 321: 992-993.
15. Wade RJ, Sambol CN. Felodipine population doseresponse and concentration-response relationships in patients with essential hypertension. Clin Pharm Ther Clin Pharm Ther 1995; 57: 569-581.
16. Alexopoulos GS, Abrams RC, Young RC et al. Cornell scale for depression in dementia. Biol Psychiatr 1988; 23: 271-284.
17. Wan B, Villard JF DOLOPLUS: Echelle d'évaluation comportementale de la douleur chez la personne âgée. Le generaliste et la gerontologie, 1999: 14.
18. Jean A, Morello R, Alix M, groupe ECPA. Evaluation de la douleur du sujet âgé hospitalisé en long séjour. Revue de geriatrie 1998; 23: 253-256.
19. Guigoz Y, Vellas B, Garry PJ. Mini Nutritional Assessment. A practical assessement tool for grading the nutritional state of elderly patients. Facts and Research in Gerontology, 1994 (Suppl 2): 1-59.
20. Folstein MF, Folstein SE. Mini mental state: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-198.
21. Puel M, Hugonot-Diener L. Présentation de l'adaptation en langue française par le GRECO d'une échelle d'évaluation cognitive, utilisée dans les démences de type Alzheimer. Presse Med 1996; 25: 1028-1032.
22. Goldberg DP. Manual of General Health Questionnaire. Windsor: NFER, 1979.
23. Bocquet H, Pons J, Gharlet JP et al. Measuring the burden for carers of dependent elderly with the Zarit inventory. Rev Epidemiol Sante Pub 1996; 44: 57-65.
24. Tribut O, Reymann JM, Polard E, Allain H, Bentué-Ferrer D. Interactions médiamenteuses chez le sujet âgé. Angeiologie 2000; 52: 25-38.